Eisai Co. Valuation Multiples

Eisai Co. Overview

About Eisai Co.

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Founded

1941

HQ

Employees

10.9K

Website

eisai.co.jp

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $5B

EBITDA: $626M

EV

$8B

Valuation Multiples

Multiples.vc

Start free trial

Eisai Co. Financials

Eisai Co. reported last 12-month revenue of $5B and EBITDA of $626M.

In the same LTM period, Eisai Co. generated $4B in gross profit, $626M in EBITDA, and $294M in net income.

Eisai Co. P&L

In the most recent fiscal year, Eisai Co. reported revenue of $5B and EBITDA of $667M.

Eisai Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX

Eisai Co. Stock Performance

Eisai Co. has current market cap of $9B, and enterprise value of $8B.

Eisai Co.'s stock price is $30.72.

Eisai Co. Valuation Multiples

Eisai Co. trades at 1.6x EV/Revenue multiple, and 12.9x EV/EBITDA.

Eisai Co. Financial Valuation Multiples

As of April 18, 2026, Eisai Co. has market cap of $9B and EV of $8B.

Equity research analysts estimate Eisai Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Eisai Co. has a P/E ratio of 29.4x.

Eisai Co. Margins & Growth Rates

Eisai Co.'s revenue in the last 12 month grew by 7%.

Eisai Co.'s revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Eisai Co.'s rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Eisai Co.'s rule of X is 29% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Eisai Co. Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Eisai Co. M&A Activity

Eisai Co. acquired XXX companies to date.

Last acquisition by Eisai Co. was on XXXXXXXX, XXXXX. Eisai Co. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Eisai Co. Investment Activity

Eisai Co. invested in XXX companies to date.

Eisai Co. made its latest investment on XXXXXXXX, XXXXX. Eisai Co. invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).